Published in Clin Exp Immunol on March 01, 1983
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
Dynamics of interaction between complement-fixing antibody/dsDNA immune complexes and erythrocytes. In vitro studies and potential general applications to clinical immune complex testing. J Clin Invest (1985) 0.92
The quantification of erythrocyte antigen sites with monoclonal antibodies. Immunology (1984) 0.87
Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum. J Exp Med (1969) 7.43
Antigenic determinants of human beta-1c and beta-1g-globulins. J Immunol (1966) 4.22
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
Preparation of red cells coated with C4 and C3 subcomponents and production of anti-C4d and anti-C3d. Vox Sang (1976) 1.15
Quantitation of red blood cell-bound C3d in normal subjects and random hospitalized patients. Br J Haematol (1981) 0.92
Purification and use of the C3d subunit C3. Transfusion (1976) 0.90
Anti-C3d antiglobulin reagents. I. Characteristics of the anti-C3c and anti-C3d responses during hyperimmunization in rabbits. Transfusion (1974) 0.88
A simple method for preparation of C3c fragment from trypsinized serum-reacted zymosan. Transfusion (1980) 0.84
Characterization of red blood cells strongly coated in vitro by C3 via the alternative pathway. Transfusion (1980) 0.81
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Alloimmunization in patients with warm autoantibodies. A retrospective study employing three donor alloabsorptions to aid in antibody detection. Transfusion (1985) 1.71
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Prevalence of HLA sensitization in female apheresis donors. Transfusion (1999) 1.70
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Naturally occurring Sin Nombre virus genetic reassortants. Virology (1995) 1.67
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
Packed red blood cells. N Engl J Med (1969) 1.60
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
Isolation, characterization and geographic distribution of Caño Delgadito virus, a newly discovered South American hantavirus (family Bunyaviridae). Virus Res (1997) 1.48
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43
Deficiency of the second component of complement associated with anaphylactoid purpura and presence of mycoplasma in the serum. Clin Exp Immunol (1973) 1.42
Complement-mediated lysis of liposomes produced by the reactive lysis procedure. Immunology (1970) 1.42
Studies on the terminal stages of complement lysis. Immunology (1973) 1.40
Complete genetic characterization and analysis of isolation of Sin Nombre virus. J Virol (1995) 1.38
Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol (1978) 1.38
The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin Exp Immunol (1995) 1.37
Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells. Eur J Immunol (1978) 1.37
An iatrogenic autoantibody: immunological responses to 'pituitary snuff' in patients with diabetes insipidus. Clin Exp Immunol (1966) 1.35
Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement (1987) 1.35
Immunoconglutinins in human saliva--a group of unusual IgA antibodies. Immunology (1970) 1.35
Structure of a soluble, glycosylated form of the human complement regulatory protein CD59. Structure (1994) 1.34
An improved purification procedure for the third component of complement and beta 1H globulin from human serum. Mol Immunol (1979) 1.34
Idiopathic acquired autoimmune hemolytic anemia. A review of forty-seven cases treated from 1955 through 1965. Am J Med (1967) 1.34
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest (1996) 1.33
Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g. J Immunol (1984) 1.32
Immunity deficiency in pathogenesis of glomerulonephritis. Lancet (1974) 1.31
Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology (2001) 1.31
Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol (1990) 1.29
Activation of the alternative complement pathway by lymphoblastoid cell lines derived from patients with Burkitt's lymphoma and infectious mononucleosis. Cell Immunol (1976) 1.28
Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitized animals. Ciba Found Symp (1986) 1.28
Allotypes of complement components in man. Transplant Rev (1976) 1.27
Inherited structural variation and linkage relationships of C7. J Immunogenet (1978) 1.26
Purification of cobra venom factor from phospholipase A contaminant. Immunology (1976) 1.25
Measles virus receptor on human T lymphocytes. Nature (1975) 1.24
Coexistence of several novel hantaviruses in rodents indigenous to North America. Virology (1995) 1.24
Inherited deficiencies of the terminal components of human complement. Immunodefic Rev (1992) 1.24
The fractionation of antigen-dependent macrophage migration inhibition and macrophage activation factors from lymph draining a tuberculin reaction. Scand J Immunol (1974) 1.24
The paraproteins in systemic capillary leak syndrome. Clin Exp Immunol (1993) 1.22
Lymphocyte cooperation. Proc R Soc Lond B Biol Sci (1971) 1.21
Erythrocyte complement receptor type 1, immune complexes, and the rheumatic diseases. Arthritis Rheum (1988) 1.21
Pregnancy and idiopathic autoimmune haemolytic anaemia: a prospective study during 6 months gestation and 3 months post-partum. Br J Haematol (1973) 1.19
The regulation of IgG subclass production in man: low serum IgG4 in inherited deficiencies of the classical pathway of C3 activation. Eur J Immunol (1988) 1.18
Restoration of specific immunological virginity. Nature (1974) 1.16
Consent and confidentiality--where are the limits? An introduction. J Med Ethics (2003) 1.15
Cellular immunity in subacute sclerosing panencephalitis. Proc R Soc Med (1974) 1.14
Lesions due to complement in lipid membranes. Nature (1971) 1.13
Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest (1975) 1.11
Atypical antigenic properties of a gamma-A myeloma protein. J Immunol (1966) 1.11
Isolation, genetic diversity, and geographic distribution of Bayou virus (Bunyaviridae: hantavirus). Am J Trop Med Hyg (1997) 1.09
The failure to show a necessary role for C3 in the in vitro antibody response. Eur J Immunol (1975) 1.08
Studies on antigenic competition. II. Abolition of antigenic competition by antibody against or tolerance to the dominant antigen: a model for antigenic competition. Immunology (1972) 1.08
Further studies on the C3b inactivator or conglutinogen activating factor (KAF). Immunochemistry (1973) 1.07
Severe immune-mediated hemolytic anemia secondary to treatment with cefotetan. Transfusion (1992) 1.07
Measurement of deoxyribonuclease I (DNase) in the serum and urine of systemic lupus erythematosus (SLE)-prone NZB/NZW mice by a new radial enzyme diffusion assay. Clin Exp Immunol (1997) 1.07